Hodgkin Lymphoma - Pipeline Review, H1 2016 - Product Image

Hodgkin Lymphoma - Pipeline Review, H1 2016

  • ID: 3643174
  • Report
  • 361 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Cell Medica Limited
  • Gamida Cell Ltd.
  • Mirati Therapeutics Inc.
  • Pfizer Inc.
  • Selvita S.A.
  • MORE
Hodgkin Lymphoma - Pipeline Review, H1 2016

Summary

The report ‘Hodgkin Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Hodgkin Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
- The report reviews pipeline therapeutics for Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Cell Medica Limited
  • Gamida Cell Ltd.
  • Mirati Therapeutics Inc.
  • Pfizer Inc.
  • Selvita S.A.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hodgkin Lymphoma Overview

Therapeutics Development

Pipeline Products for Hodgkin Lymphoma - Overview

Pipeline Products for Hodgkin Lymphoma - Comparative Analysis

Hodgkin Lymphoma - Therapeutics under Development by Companies

Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes

Hodgkin Lymphoma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Hodgkin Lymphoma - Products under Development by Companies

Hodgkin Lymphoma - Products under Investigation by Universities/Institutes

Hodgkin Lymphoma - Companies Involved in Therapeutics Development

4SC AG

Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ADC Therapeutics Sarl

Affimed Therapeutics AG

Arbutus Biopharma Corporation

Bellicum Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Cell Medica Limited

Cellular Biomedicine Group, Inc.

Constellation Pharmaceuticals, Inc.

Curis, Inc.

Faron Pharmaceuticals Oy

Fate Therapeutics, Inc.

Gamida Cell Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Merck & Co., Inc.

Mirati Therapeutics Inc.

Molecular Templates Inc.

NantKwest, Inc.

Novartis AG

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

Pharmacyclics, Inc.

Philogen S.p.A.

Rich Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Selvita S.A.

Sigma-Tau S.p.A.

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Syndax Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

TG Therapeutics, Inc.

Theravectys SA

Trillium Therapeutics Inc.

Hodgkin Lymphoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(INCB-039110 + INCB-040093) - Drug Profile

abexinostat hydrochloride - Drug Profile

acalisib - Drug Profile

ADCT-301 - Drug Profile

AFM-13 - Drug Profile

Alocrest - Drug Profile

aNK Program - Drug Profile

azacitidine - Drug Profile

BMS-986016 - Drug Profile

BPX-501 - Drug Profile

brentuximab vedotin - Drug Profile

CBM-C30.1 - Drug Profile

Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile

Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile

Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile

Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile

CMD-003 - Drug Profile

CPI-0610 - Drug Profile

CUDC-907 - Drug Profile

entinostat - Drug Profile

Epstein-Barr virus vaccine - Drug Profile

Ferritarg - Drug Profile

FP-1304 - Drug Profile

FT-1050 - Drug Profile

haNK Program - Drug Profile

INCB-40093 - Drug Profile

Indimitecan - Drug Profile

Indotecan hydrochloride - Drug Profile

Iomab-B - Drug Profile

ipilimumab - Drug Profile

ixazomib citrate - Drug Profile

lirilumab - Drug Profile

MK-2206 - Drug Profile

mocetinostat - Drug Profile

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile

Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile

NiCord - Drug Profile

nivolumab - Drug Profile

NSC-678515 - Drug Profile

panobinostat - Drug Profile

pembrolizumab - Drug Profile

PF-06801591 - Drug Profile

PNK-007 - Drug Profile

procarbazine hydrochloride - Drug Profile

radretumab - Drug Profile

Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile

resminostat - Drug Profile

ricolinostat - Drug Profile

RP-323 - Drug Profile

ruxolitinib phosphate - Drug Profile

SEL-24B489 - Drug Profile

SL-101 - Drug Profile

SL-501 - Drug Profile

temsirolimus - Drug Profile

TGR-1202 - Drug Profile

TKM-PLK1 - Drug Profile

TTI-621 - Drug Profile

Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile

Hodgkin Lymphoma - Recent Pipeline Updates

Hodgkin Lymphoma - Dormant Projects

Hodgkin Lymphoma - Discontinued Products

Hodgkin Lymphoma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hodgkin Lymphoma, H1 2016

Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016

Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2016

Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016

Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016

Hodgkin Lymphoma - Pipeline by Arbutus Biopharma Corporation, H1 2016

Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016

Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016

Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H1 2016

Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Curis, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Faron Pharmaceuticals Oy, H1 2016

Hodgkin Lymphoma - Pipeline by Fate Therapeutics, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2016

Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016

Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2016

Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016

Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2016

Hodgkin Lymphoma - Pipeline by Rich Pharmaceuticals, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Selvita S.A., H1 2016

Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2016

Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016

Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016

Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016

Hodgkin Lymphoma - Dormant Projects, H1 2016

Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016

Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016

Hodgkin Lymphoma - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Hodgkin Lymphoma, H1 2016

Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
4SC AG
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed Therapeutics AG
Arbutus Biopharma Corporation
Bellicum Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Cell Medica Limited
Cellular Biomedicine Group, Inc.
Constellation Pharmaceuticals, Inc.
Curis, Inc.
Faron Pharmaceuticals Oy
Fate Therapeutics, Inc.
Gamida Cell Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Merck & Co., Inc.
Mirati Therapeutics Inc.
Molecular Templates Inc.
NantKwest, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmacyclics, Inc.
Philogen S.p.A.
Rich Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Selvita S.A.
Sigma-Tau S.p.A.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Syndax Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
Theravectys SA
Trillium Therapeutics Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll